This week, star London-based fund manager Neil Woodford talked about his recent poor performance, mainly as a result of the huge losses suffered in his holding in Provident Financial.
Below is the chart, which tells its own sorry story:
Showing posts with label Valeant Pharmaceuticals. Show all posts
Showing posts with label Valeant Pharmaceuticals. Show all posts
Saturday, September 09, 2017
Friday, March 25, 2016
Slave to the system
Whenever a trend follower captures a big winning trade, outsiders often wonder if it down to pure luck, skill or something else?
In a lot of cases, trends can start to develop in spite of the current sentiment and beliefs of many of the market participants.
Trend followers however approach the markets in a unemotional state - if their method tells them to enter a trade at a certain price level, they enter. Similarly, if their method tells them to exit at a certain price level, they exit.
In a lot of cases, trends can start to develop in spite of the current sentiment and beliefs of many of the market participants.
Trend followers however approach the markets in a unemotional state - if their method tells them to enter a trade at a certain price level, they enter. Similarly, if their method tells them to exit at a certain price level, they exit.
Sunday, March 20, 2016
Bill Ackman and Valeant Pharmaceuticals
The big news this week was the bloody nose that Bill Ackman and his Pershing Square fund received regarding their investment in Valeant Pharmaceuticals.
Following a dire update, the stock plunged to levels not seen since 2011, and has dropped almost 90% (yes, you read that correctly) from its all-time highs above $260 back in August.
Following a dire update, the stock plunged to levels not seen since 2011, and has dropped almost 90% (yes, you read that correctly) from its all-time highs above $260 back in August.
Subscribe to:
Posts (Atom)